Clinical Study of Umbilical Cord Mesenchymal Stem Cells Infusion for Aging Frailty

Phase 1/2 Completed 30 enrolled Shanghai East Hospital

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this clinical study is to answer the questions: 1. Is the proposed intervention safe? 2. Is the proposed intervention effective in improving the healthy status of subjects with aging frailty?

Timeline

Start: 2020-06-01
Primary completion: 2021-12-30
Completion: 2022-03-01

Publications

Zhu Y, Huang C, Zheng L, Li Q, Ge J, Geng S, Zhai M, Chen X, Yuan H, Li Y, Jia W, Sun K, Li Y, Ye T, Zhao Z, Liu H, Liu Z, Jiang H. Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study. Stem Cell Res Ther. 2024 Apr 29;15(1):122. doi: 10.1186/s13287-024-03707-2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	human umbilical cord mesenchymal stem cells	Cell therapy	1e+06 cells/kg	Intravenous

Indications

No indication recorded.